S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
The single greatest medical breakthrough of all time? (Ad)
Nigeria's central bank chief arrested after being suspended by president
North Dakota tribe buys idle oil pipeline from Enbridge
America's Worst Nightmare: A Major Financial Crisis Looms (Ad)
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
The single greatest medical breakthrough of all time? (Ad)
Nigeria's central bank chief arrested after being suspended by president
North Dakota tribe buys idle oil pipeline from Enbridge
America's Worst Nightmare: A Major Financial Crisis Looms (Ad)
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
The single greatest medical breakthrough of all time? (Ad)
Nigeria's central bank chief arrested after being suspended by president
North Dakota tribe buys idle oil pipeline from Enbridge
America's Worst Nightmare: A Major Financial Crisis Looms (Ad)
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
The single greatest medical breakthrough of all time? (Ad)
Nigeria's central bank chief arrested after being suspended by president
North Dakota tribe buys idle oil pipeline from Enbridge
America's Worst Nightmare: A Major Financial Crisis Looms (Ad)
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia

Century Therapeutics (IPSC) Stock Forecast, Price & News

$3.34
-0.07 (-2.05%)
(As of 06/9/2023 ET)
Compare
Today's Range
$3.26
$3.53
50-Day Range
$2.91
$3.44
52-Week Range
$2.81
$14.00
Volume
49,777 shs
Average Volume
79,626 shs
Market Capitalization
$199.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

Century Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
468.9% Upside
$19.00 Price Target
Short Interest
Bearish
6.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$295,202 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.07) to ($1.95) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

822nd out of 987 stocks

Biological Products, Except Diagnostic Industry

134th out of 160 stocks


IPSC stock logo

About Century Therapeutics (NASDAQ:IPSC) Stock

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-102, a CAR-iT targeting CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-107, an iPSC-derived Nectin-4 CAR gamma delta T-cell therapy product candidate; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Receive IPSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

IPSC Stock News Headlines

[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
Analyst Ratings for Century Therapeutics
Century Therapeutics Announces Leadership Changes
EF Hutton Sticks to Their Buy Rating for Century Therapeutics (IPSC)
See More Headlines

IPSC Price History

IPSC Company Calendar

Last Earnings
3/16/2023
Today
6/10/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IPSC
Fax
N/A
Employees
163
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+468.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-130,930,000.00
Net Margins
-2,127.33%
Pretax Margin
-2,105.44%

Debt

Sales & Book Value

Annual Sales
$5.20 million
Book Value
$5.13 per share

Miscellaneous

Free Float
55,053,000
Market Cap
$199.00 million
Optionable
Not Optionable
Beta
0.59

Key Executives

  • Dr. Michael C. Diem M.D. (Age 52)
    Chief Financial Officer
    Comp: $650.66k
  • Dr. Adrienne Farid Ph.D. (Age 61)
    COO & Head of Early Devel.
    Comp: $650.66k
  • Dr. Gregory Russotti Ph.D. (Age 56)
    Interim Pres & CEO
  • Dr. Luis Borges (Age 61)
    Chief Scientific Officer
  • Mr. Kenneth J. Dow J.D.
    Sr. VP of Gen. Counsel
  • Dr. Shane Williams Ph.D.
    Chief People Officer
  • Dr. Hyam I. Levitsky M.D. (Age 65)
    Pres of R&D
  • Mr. Mark Wallet
    Head of Immunology & VP
  • Michael Naso Ph.D.
    Sr. VP of Cell Engineering
  • Mr. Douglas Carr CPA
    Sr. VP of Fin. & Operations and Sec.













IPSC Stock - Frequently Asked Questions

Should I buy or sell Century Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IPSC shares.
View IPSC analyst ratings
or view top-rated stocks.

What is Century Therapeutics' stock price forecast for 2023?

8 brokers have issued 1-year target prices for Century Therapeutics' shares. Their IPSC share price forecasts range from $14.00 to $28.00. On average, they predict the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 468.9% from the stock's current price.
View analysts price targets for IPSC
or view top-rated stocks among Wall Street analysts.

How have IPSC shares performed in 2023?

Century Therapeutics' stock was trading at $5.13 at the start of the year. Since then, IPSC shares have decreased by 34.9% and is now trading at $3.34.
View the best growth stocks for 2023 here
.

When is Century Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our IPSC earnings forecast
.

How were Century Therapeutics' earnings last quarter?

Century Therapeutics, Inc. (NASDAQ:IPSC) announced its quarterly earnings results on Thursday, March, 16th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.05. The business had revenue of $0.52 million for the quarter, compared to the consensus estimate of $2.80 million. Century Therapeutics had a negative net margin of 2,127.33% and a negative trailing twelve-month return on equity of 39.33%.

When did Century Therapeutics IPO?

(IPSC) raised $201 million in an IPO on Friday, June 18th 2021. The company issued 10,600,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

What is Century Therapeutics' stock symbol?

Century Therapeutics trades on the NASDAQ under the ticker symbol "IPSC."

Who are Century Therapeutics' major shareholders?

Century Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (8.97%), BlackRock Inc. (2.37%), Geode Capital Management LLC (0.71%), State Street Corp (0.62%), Renaissance Technologies LLC (0.26%) and New York Life Investment Management LLC (0.22%). Insiders that own company stock include Eli Casdin, Luis Borges and Versant Venture Capital Vi, L.
View institutional ownership trends
.

How do I buy shares of Century Therapeutics?

Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Century Therapeutics' stock price today?

One share of IPSC stock can currently be purchased for approximately $3.34.

How much money does Century Therapeutics make?

Century Therapeutics (NASDAQ:IPSC) has a market capitalization of $199.00 million and generates $5.20 million in revenue each year. The company earns $-130,930,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.

How many employees does Century Therapeutics have?

The company employs 163 workers across the globe.

How can I contact Century Therapeutics?

The official website for the company is www.centurytx.com. The company can be reached via phone at 267-817-5790 or via email at investor.relations@centurytx.com.

This page (NASDAQ:IPSC) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -